Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00154375
First received: September 9, 2005
Last updated: April 19, 2011
Last verified: April 2011
  Purpose

This is a Phase III study comparing Imatinib mesylate and hydroxyurea combination therapy with hydroxyurea monotherapy in patients with temozolomide resistant progressive glioblastoma.


Condition Intervention Phase
Glioblastoma Multiforme
Astrocytoma
Drug: Imatinib mesylate
Drug: Hydroxyurea
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Percentage of Participants With Progression Free Survival (PFS) During the Study Duration [ Time Frame: 6 months -1 year ] [ Designated as safety issue: No ]
    PFS was defined as the time from the date of randomization to the date of the first documented progression according to the MacDonald criteria, or death due to any cause. MacDonald criteria are standard criteria in neurooncology. Tumor assessment was made according to the adapted MacDonald criteria based on the combined evaluation of 1) assessment of the MRI scan for measurable, evaluable, and new lesions (made by the independent external expert too), 2) overall assessment of neurological performance (made by the investigator), 3) concomitant steroid use (as reported by the investigator).


Secondary Outcome Measures:
  • Number of Participants With Death, Other Serious or Clinically Significant Adverse Events (AEs) or Related Discontinuations [ Time Frame: 6 months - 1 year ] [ Designated as safety issue: Yes ]
    National Cancer Institute (NCI)/ National Institute of Health (NIH) provides a grading (severity) scale for each AE term. Grade 3 refers to severe AE and Grade 4 refers to life-threatening or disabling AE. According to FDA 21CFR 314.80, a serious adverse event (SAE) is described as any adverse event that leads to death, is life threatening ( NIH criteria Grade 4), causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above.


Enrollment: 240
Study Start Date: October 2004
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Imatinib mesylate + hydroxyurea (HU)
Imatinib was supplied as 100 mg and 400 mg tablets. Patients in the combination arm were instructed to take a daily oral imatinib dose of 600 mg (600 mg at lunch time) and a daily oral hydroxyurea (HU) dose of 1000 mg (500 mg twice daily; in the morning and at bed time). Every 6 weeks after randomization based on assessment of therapeutic response, either patients continued with above mentioned dosing regimen or switched to receive a daily dose of 800 mg imatinib with 1000 mg HU. Patients were instructed to split the intake, taking 400 mg imatinib with 500 mg HU in the morning, then the same in the evening.
Drug: Imatinib mesylate
Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.
Other Name: Glivec®
Drug: Hydroxyurea
Other Name: Litalir®
Active Comparator: Hydroxyurea alone
1500 mg/day of HU given as 500 mg 3 times daily. Every 6 weeks after randomization and based on assessment of therapeutic response, the patients were either switched to combination arm or continued in monotherapy arm of hydroxyurea.
Drug: Hydroxyurea
Other Name: Litalir®

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent prior to initiation of any study procedure.
  • Patients >= 18 years of age.
  • Histological confirmed diagnosis of glioblastoma multiforme / astrocytoma World Health Organization (WHO) grade IV by a reference pathologist
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
  • Adequate hepatic, renal and bone marrow function as defined by the following: total bilirubin < 1.5 x Upper Limit of Normal (ULN), ALT and AST < 2.5 x ULN, creatinine < 1.5 x ULN, absolute neutrophil count > 1.5 x109/L, platelets > 100 x109/L and hemoglobin > 10 g/dL.
  • Female patients of childbearing potential with a negative pregnancy test within 7 days of initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential who agree to employ an effective barrier method of birth control throughout the study, and for up to 3 months following discontinuation of study drug.
  • Life expectancy of >3 months.
  • MRI available every 6 weeks for disease management
  • No intercerebral inflammation
  • Irradiation therapy 54 to 62 gy finished or less according to national standard
  • Chemotherapy at least 1 temozolomide containing regimen finished, no established chemotherapy regiment available and progression under chemotherapy or in between 6 months following the last chemotherapy.
  • Leucocytes > 2.500/µl, to be controlled once a week
  • Thrombocytes > 80.000/µl, to be controlled once a week
  • Ensured compliance
  • Patients who had a second or third resection after disease progression cannot be included earlier than 2 weeks following the resection. MRI should be performed not later than 72 h post operation. If patients are to be included later than 4 weeks after the resection, a new baseline MRI must be performed.

Exclusion Criteria:

  • Female patients who are pregnant or breast-feeding.
  • Patients who have been treated with any investigational agent(s) within 28 days of the first day of administration of study drug.
  • Patients with uncontrolled medical disease such as diabetes mellitus, thyroid dysfunction, neuropsychiatric disorders, infection, angina or Grade 3 or 4 cardiac problems as defined by the New York Heart Association Criteria.
  • Patients with other malignant disorders.
  • Patient with acute or known chronic liver disease (i.e., chronic active hepatitis, cirrhosis).
  • Patients who are known to be HIV positive (no specific tests are required for confirmation of eligibility).
  • Expected incompliance according to treatment, treatment diary and examination schedule
  • Not confirmed histological diagnosis glioblastoma multiforme/astrocytoma WHO grade IV
  • Other drugs with potential cytostatic main or side effect
  • No or inadequate chemotherapy or irradiation therapy
  • Patients without hematological recovery after previous chemotherapy who have been treated with Chemotherapy within 28 days of the first day of administration of study drug.

Other protocol-specific inclusion /exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00154375

Locations
Germany
Novartis Investigative Site
Duelmen, Germany
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: External Affairs, Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00154375     History of Changes
Other Study ID Numbers: CSTI571BDE40
Study First Received: September 9, 2005
Results First Received: January 13, 2011
Last Updated: April 19, 2011
Health Authority: European Union: European Medicines Agency
Germany: Federal Institute for Drugs and Medical Devices
Australia: Therapeutic Goods Administration
Sweden: Medical Projects Agency
Denmark: Danish Medicines Agency
Norway: Norwegian Medicines Agency
Finland: Finnish Medicines Agency

Keywords provided by Novartis:
Open label
Imatinib mesylate
hydroxyurea
temozolomide
resistant
protein tyrosine kinases
adenocarcinoma
glioblastoma multiforme
astrocytoma
brain tumor
brain cancer

Additional relevant MeSH terms:
Astrocytoma
Glioblastoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Temozolomide
Imatinib
Hydroxyurea
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antisickling Agents
Hematologic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Antineoplastic Agents, Alkylating
Alkylating Agents
Protein Kinase Inhibitors

ClinicalTrials.gov processed this record on July 23, 2014